Skip to search formSkip to main contentSkip to account menu

Margetuximab

Known as: Immunoglobulin G1, Anti-(human Neu (Receptor)) (Human-Mus musculus Monoclonal MGAH22 Clone ch4D5 Heavy Chain), Disulfide with Human-Mus musculus Monoclonal MGAH22 Clone ch4D5 Light Chain, Dimer 
A Fc-domain optimized IgG monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2) with potential immunomodulating… 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

MGAH22
NCIt Antineoplastic Agent Terminologyantigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Solving the Puzzle of Treatment Resistance in Patients with HER2-Positive Metastatic Breast Cancer – New Approaches to HER Target Family Network
DOI: 10.14744/ejmo.2020.93349 EJMO 2020;4(2):126–134 
2020
2020
Abstract P1-18-04: Phase 3 SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: Infusion time…
Review
2020
Review
2020
HER2-positive breast cancer – Available anti-HER2 therapies and new agents under investigation
Introduction and objectives. Breast cancer (BC) is the most common malignancy and the leading cause of cancer death among women… 
2019
2019
"Super Trastuzumab" Extends PFS in Late-Line Breast Cancer.
Margetuximab outperformed trastuzumab in a phase III, head-to-head trial of the two anti-HER2 agents among patients with HER2… 
2017
2017
Abstract OT1-02-07: SOPHIA: A phase 3, randomized study of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy in the treatment of patients with HER2+ metastatic breast cancer
Background: Despite significant advances in targeted therapy, HER2+ metastatic breast cancer (MBC) remains incurable. Ideal…